AngioDynamics (NASDAQ:ANGO) Stock Rating Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of AngioDynamics (NASDAQ:ANGO) from a buy rating to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.

Several other brokerages also recently commented on ANGO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Zacks Research raised AngioDynamics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. Canaccord Genuity Group restated a “buy” rating and set a $20.00 price target on shares of AngioDynamics in a report on Friday. Finally, HC Wainwright upped their price target on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.50.

AngioDynamics Stock Performance

NASDAQ:ANGO opened at $11.52 on Friday. AngioDynamics has a fifty-two week low of $9.39 and a fifty-two week high of $16.29. The firm has a market cap of $484.42 million, a PE ratio of -14.77 and a beta of 0.30. The business has a 50 day moving average price of $15.32 and a 200-day moving average price of $13.10.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.07. The company had revenue of $80.92 million for the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.43%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Research analysts predict that AngioDynamics will post -0.25 EPS for the current year.

Insiders Place Their Bets

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the transaction, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. This represents a 26.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

A number of hedge funds have recently added to or reduced their stakes in ANGO. Integrated Wealth Concepts LLC purchased a new stake in AngioDynamics during the second quarter valued at $38,000. Legal & General Group Plc bought a new position in AngioDynamics in the second quarter worth approximately $45,000. Public Employees Retirement System of Ohio bought a new position in AngioDynamics in the second quarter worth approximately $64,000. State of Wyoming purchased a new position in shares of AngioDynamics during the 2nd quarter worth $72,000. Finally, Inceptionr LLC purchased a new position in shares of AngioDynamics during the 1st quarter worth $115,000. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Key AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Adjusted earnings beat expectations. AngioDynamics reported fiscal Q1 2027 adjusted EPS of a $0.04 loss, better than the $0.11 loss analysts expected. Revenue reached $80.9 million, slightly above consensus and up 6.9% year over year. Zacks earnings report
• Positive Sentiment: Med Tech growth and margins were strong. Med Tech sales rose 13.2% to $39.9 million, led by 14.7% growth in Auryon sales and 29% growth in NanoKnife sales. Gross margin expanded 410 basis points to 59.4%, while the GAAP net loss narrowed from the prior year. The company also received FDA IDE approval for a NanoKnife feasibility study in benign prostatic hyperplasia. AngioDynamics fiscal Q1 results
• Positive Sentiment: Canaccord reaffirmed its Buy rating and set a $20 price target, implying substantial potential upside from the referenced share price. Benzinga report
• Neutral Sentiment: Fiscal 2027 guidance was reiterated: revenue of $336 million to $341 million and an adjusted EPS loss of $0.24 to $0.29. The outlook remains broadly in line with analyst expectations, but it does not yet indicate a return to profitability. Seeking Alpha guidance report
• Negative Sentiment: Leadership uncertainty is weighing on sentiment. Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The transition adds execution risk even as operating momentum improves. CEO appointment announcement
• Negative Sentiment: Profitability and cash flow remain concerns. AngioDynamics posted a GAAP net loss of $7.1 million and used $15.3 million of operating cash during the quarter. These issues likely overshadowed the adjusted EPS and revenue beats. Reported short-interest data showing zero shares appears inconsistent and should be treated cautiously.

About AngioDynamics

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.